DHS S&T’s SVIP has awarded $105,877 in Phase 1 funding for Bloodstone Division, LLC’s development of an anti-viral disinfectant under the SVIP Emerging Needs: COVID-19 Response & Future Mitigation solicitation.
news, journals and articles from all over the world.
DHS S&T’s SVIP has awarded $105,877 in Phase 1 funding for Bloodstone Division, LLC’s development of an anti-viral disinfectant under the SVIP Emerging Needs: COVID-19 Response & Future Mitigation solicitation.